Literature DB >> 23153688

Hypertension caused by primary hyperaldosteronism: increased heart damage and cardiovascular risk.

María Abad-Cardiel1, Beatriz Alvarez-Álvarez, Loreto Luque-Fernandez, Cristina Fernández, Arturo Fernández-Cruz, Nieves Martell-Claros.   

Abstract

INTRODUCTION AND
OBJECTIVES: Primary hyperaldosteronism is the most common cause of secondary hypertension. Elevated aldosterone levels cause heart damage and increase cardiovascular morbidity and mortality. Early diagnosis could change the course of this entity. The objective of this report was to study the clinical characteristics, cardiac damage and cardiovascular risk associated with primary hyperaldosteronism.
METHODS: We studied 157 patients with this diagnosis. We analyzed the reason for etiological investigation, and the routinely performed tests, including echocardiography. We used a cohort of 720 essential hypertensive patients followed in our unit for comparison.
RESULTS: Compared with essential hypertensive patients, those with hyperaldosteronism were younger (56.9 [11.7] years vs 60 [14.4] years; P<.001), had higher blood pressure prior to the etiological diagnosis (136 [20.6] mmHg vs 156 [23.2] mmHg), more frequently had a family history of early cardiovascular disease (25.5% vs 2.2%; P<.001), and had a higher prevalence of concentric left ventricular hypertrophy (69% vs 25.7%) and higher cardiovascular risk. Specific treatment resulted in optimal control of systolic and diastolic blood pressures (from 150.7 [23.0] mmHg and 86.15 [14.07] mmHg to 12.69 [15.3] mmHg and 76.34 [9.7] mmHg, respectively). We suspected the presence of hyperaldosteronism because of resistant hypertension (33.1%), hypokalemia (38.2%), and hypertensive crises (12.7%). Only 4.6% of these patients had been referred from primary care with a suspected diagnosis of hyperaldosteronism.
CONCLUSIONS: Hyperaldosteronism should be suspected in cases of resistant hypertension, hypokalemia and hypertensive crises. The diagnosis of hyperaldosteronism allows better blood pressure control. The most prevalent target organ damage is left ventricular hypertrophy.
Copyright © 2012 Sociedad Española de Cardiología. Published by Elsevier Espana. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23153688     DOI: 10.1016/j.recesp.2012.07.025

Source DB:  PubMed          Journal:  Rev Esp Cardiol (Engl Ed)        ISSN: 1885-5857


  7 in total

1.  Larger ascending aorta in primary aldosteronism: a 3-year prospective evaluation of adrenalectomy vs. medical treatment.

Authors:  Guido Zavatta; Guido Di Dalmazi; Carmine Pizzi; Giovanni Bracchetti; Cristina Mosconi; Caterina Balacchi; Uberto Pagotto; Valentina Vicennati
Journal:  Endocrine       Date:  2018-11-14       Impact factor: 3.633

2.  NP-59 test for preoperative localization of primary hyperaldosteronism.

Authors:  Marcello Di Martino; Iñigo García Sanz; Jose Luis Muñoz de Nova; Cristina Marín Campos; Miguel Martínez Martín; Luis Domínguez Gadea
Journal:  Langenbecks Arch Surg       Date:  2017-02-21       Impact factor: 3.445

3.  [Etiology of endocrine arterial hypertensions: about a series of cases].

Authors:  Naima Bouznad; Ghizlane El Mghari; Nawal El Ansari
Journal:  Pan Afr Med J       Date:  2016-04-07

4.  Arterial stiffness and blood pressure improvement in aldosterone-producing adenoma harboring KCNJ5 mutations after adrenalectomy.

Authors:  Chia-Hui Chang; Ya-Hui Hu; Yao-Chou Tsai; Che-Hsiung Wu; Shuo-Meng Wang; Lian-Yu Lin; Yen-Hung Lin; Fumitoshi Satoh; Kwan-Dun Wu; Vin-Cent Wu
Journal:  Oncotarget       Date:  2017-05-02

5.  Atractylenolide-I covalently binds to CYP11B2, selectively inhibits aldosterone synthesis, and improves hyperaldosteronism.

Authors:  Wenjuan Liu; Zhenqiang Li; Simeng Chu; Xiaoyao Ma; Xiaoying Wang; Min Jiang; Gang Bai
Journal:  Acta Pharm Sin B       Date:  2021-09-21       Impact factor: 11.413

6.  Cost-Effectiveness of Therapeutic Drug Monitoring in Diagnosing Primary Aldosteronism in Patients With Resistant Hypertension.

Authors:  Alejandro Velasco; Oliver Chung; Fayez Raza; Ambarish Pandey; Stephanie Brinker; Debbie Arbique; Angela Price; Yair Lotan; Sandeep R Das; Wanpen Vongpatanasin
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-04-27       Impact factor: 3.738

7.  Reversible heart rhythm complexity impairment in patients with primary aldosteronism.

Authors:  Yen-Hung Lin; Vin-Cent Wu; Men-Tzung Lo; Xue-Ming Wu; Chi-Sheng Hung; Kwan-Dun Wu; Chen Lin; Yi-Lwun Ho; Michael Stowasser; Chung-Kang Peng
Journal:  Sci Rep       Date:  2015-08-18       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.